| Trial ID: | L3312 |
| Source ID: | NCT02012166
|
| Associated Drug: |
Mk-0893 10 Mg
|
| Title: |
A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: MK-0893 10 mg|DRUG: MK-0893 40 mg|DRUG: MK-0893 200 mg|DRUG: MK-0893 1000 mg|DRUG: Placebo|BIOLOGICAL: Sandostatine®|BIOLOGICAL: Insulin|BIOLOGICAL: Glucagon
|
| Outcome Measures: |
Primary: Post-infusion Incremental Glucose Area Under the Plasma Concentration Versus Time Curve [AUC0-240 min] Study Part 1, Up to 76 hours postdose|Post-infusion Incremental Glucose Area Under the Plasma Concentration Versus Time Curve [AUC0-240 min] Study Part 2, Up to 124 hours postdose | Secondary: Number of Participants With An Adverse Event (AE), Up to 12 weeks|Number of Participants Who Discontinued Study Treatment Due To AEs, Up to 21 days of each treatment period
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
MALE
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
18
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2005-07
|
| Completion Date: |
2005-12
|
| Results First Posted: |
|
| Last Update Posted: |
2015-08-19
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT02012166
|
